Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Conatus Pharmaceutic (CNAT)

3.62 0.32 (9.7%)

04-25 16:00

Open:

3.31

Pre. Close:

3.3

High:

3.67

Low:

3.3

Volume:

864,145

Market Cap:

109M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

3.675 - 3.696

3.696 - 3.715

Low:

3.25 - 3.275

3.275 - 3.297

Close:

3.581 - 3.62

3.62 - 3.656

Technical analysis  (as of: 2018-04-25 4:25:46 PM)

Overall:

      

Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.

Target:

Six months: 6.14     One year: 7.60

Support:

Support1: 3.22    Support2: 2.68

Resistance:

Resistance1: 5.25    Resistance2: 6.51

Pivot:

3.76

Moving Averages:

MA(5): 3.51     MA(20): 4.27

MA(100): 5.04     MA(250): 5.28

MACD:

MACD(12,26): -0.60     Signal(12,26,9): -0.58

%K %D:

%K(14,3): 12.38     %D(3): 6.36

RSI:

RSI(14): 33.08

52-Week:

High: 9.4  Low: 3.22  Change(%): -58.7

Average Vol(K):

3-Month: 77608  10-Days 66924

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
CNAT has closed above bottom band by 34.8%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to CNAT's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-04-24T15:03:40-04:00
Conatus Pharmaceuticals; Upcoming Phase 2b Liver Results And Other Pipeline Prospects Makes It A Compelling Buy

2018-04-19T13:50:23-04:00
Your Daily Pharma Scoop: Conatus Data, Solid Biosciences' SGT-001, Ultragenyx's Crysvita Approved

2018-04-18T08:14:40-04:00
Conatus Pharma's IDN-7314 shows encouraging action in preclinical studies; shares up 4% premarket

2018-04-10T08:00:00-04:00
3 Things In Biotech, April 9: Clovis Hunts Anew, Conatus Falters, Newlink Soul Searches

2018-04-09T17:36:07-04:00
After Hours Gainers / Losers (04/09/2018)

2018-04-06T16:15:20-04:00
Conatus: What's Next For This Small-Cap Potential NASH Play?

2018-04-06T11:36:02-04:00
Conatus Falls On Phase 2 Data, But There Is More To The Story

2018-04-06T11:18:40-04:00
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

30.06

Shares Float (M)

29.89

% Held by Insiders

0.60

% Held by Institutions

46.60

Shares Short (K)

1065

Shares Short Prior Month (K)

1460

Stock Financials

EPS

-0.610

EPS Est. Current Year

-0.530

EPS Est. Next Year

0.700

EPS Est. Next Quarter

-0.150

Forward EPS

0.530

Book Value (p.s.)

3.830

PEG Ratio

-0.15

Profit Margin

-48.54

Operating Margin

-49.61

Return on Assets (ttm)

-21.2

Return on Equity (ttm)

-69.9

Qtrly Rev. Growth

1001.9

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.415

Qtrly Earnings Growth

Operating Cash Flow (M)

-33.21

Levered Free Cash Flow (M)

-18.55

atoplab.com

Valuation

P/E

-5.93

P/E Growth Ratio

0.10

P/BV

0.95

P/S

87755800.00

P/CF

-3.28

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.